Trial Profile
A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Robatumumab (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough Research Institute
- 19 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 30 May 2019 This trial has been discontinued in Spain, Norway, according to European Clinical Trials Database.